Nutra Pharma’s CEO, Rik J. Deitsch was interviewed for the website, Wall Street Reporter – providing updates on the Company’s activities and goals. October 28, 2011 — Coral Springs, Florida — Nutra Pharma Corporation (OTCBB: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV/AIDS), Adrenomyeloneuropathy (AMN) and Pain, [...]

Read Full Post »

Nutra Pharma has been issued a patent by the U.S. Patent and Trademark Office that protects their therapy for Multiple Sclerosis (MS). The patent is entitled, “Modified anticholinergic neurotoxins as modulators of the autoimmune reaction.” October 19, 2011 — Coral Springs, Florida — Nutra Pharma Corporation (OTCBB: NPHC), a biotechnology company that is developing treatments [...]

Read Full Post »

A new research study reported in the Journal of Pain shows that acute and chronic lower back pain have distinct components. Thanks to these findings, doctors may become better able to predict which cases of acute pain will turn into chronic pain (2011;12:792-800). [Pain Medicine News, September 2011, volume 9:09] Acute pain is defined as [...]

Read Full Post »

Nutra Pharma announced today that DNAA, Inc will serve as their Distributor in Panama for its Nyloxin-branded pain relievers. Coral Springs, FL. – October 14, 2011 – Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain announced today that it [...]

Read Full Post »